Diana I. Brixner, RPh, PhD, FAMCP

Languages

  • English
  • German

Academic Information

  • Departments: Pharmacotherapy - Professor
  • Divisions: Health System Innovation and Research, Pediatric Clinical Pharmacology
  • Cancer Center Programs: Affiliate, non-programmatically aligned

Academic Office Information

  • 801-581-3182
  • L.S. Skaggs Pharmacy Institute
    Department of Pharmacotherapy
    30 S 2000 E, Room: 4781
    Salt Lake City, UT 84112

Academic Bio

Currently I am a Professor in the Department of Pharmacotherapy, Adjunct Professor in the Department of Population Health Sciences and Pediatrics in the Divisions of Health Systems Innovation Research and Clinical Pharmacology and Executive Director of the Pharmacotherapy Outcomes Research Center at the University of Utah. My research focus is on the design, conduct, and communication of pharmacoeconomic and outcomes research studies to demonstrate the value of pharmaceutical and related therapies from the perspective of the private and public payer. I am also a Research Associate at the Institute of Public Health, Medical Decision Making and Health Technology Assessment in the Department of Public Health and Health Technology Assessment at UMIT - University for Health Sciences, Medical Informatics and Technology in Hall i.T., Austria. This appointment supports my international collaborations in oncology research, personalized medicine and value assessment. During my career, I have published over 100 articles in peer-reviewed journals, authored three book chapters, have one issued patent, and have been an invited speaker at a variety of national and international professional meetings. I am a founding member, served on the Executive Board, and currently serve on the Health Policy and Science Council and am a past president of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR). In addition, I am a long-standing member and immediate past president of the Academy of Managed Care Pharmacy (AMCP), and am also a Fellow of the Academy.

Education History

Type School Degree
Other Training University of Health Sciences, Medical Informatics and Technology
Introduction to Health Technology
Certificate
Certification University of Health Sciences, Medical Informatics and Technology (UMIT)
Epidemiology
Certificate
Certification University of Health Sciences, Medical Informatics and Technology
Health Sciences, Hall in Tirol, Austria
Certificate
Doctoral Training University of Utah
Medicinal Chemistry
Ph.D.
Undergraduate University of Rhode Island
Pharmacy
B.S.

Global Impact

Education History

Type School Degree Country
Other Training University of Health Sciences, Medical Informatics and Technology
Introduction to Health Technology
Certificate Austria
Certification University of Health Sciences, Medical Informatics and Technology (UMIT)
Epidemiology
Certificate Austria
Certification University of Health Sciences, Medical Informatics and Technology
Health Sciences, Hall in Tirol, Austria
Certificate Austria

Selected Publications

Journal Article

  1. Kim K, Unni S, McAdam-Marx C, Thomas SM, Sterling KL, Olsen CJ, Johnstone B, Mitchell M, Brixner D (2019 Mar). Influence of Treatment Intensification on A1c in Patients with Suboptimally Controlled Type 2 Diabetes After 2 Oral Antidiabetic Agents. J Manag Care Spec Pharm, 25(3), 314-322.
  2. Chang A, Nelson R, Brixner D (2019 Feb 9). Advancing pharmacy practice by reducing gaps in pharmacogenetic education. Am J Health Syst Pharm, 76(5), 320-326.
  3. Tak CR, Biltaji E, Kohlmann W, Maese L, Hainaut P, Villani A, Malkin D, Sherwin CMT, Brixner DI, Schiffman JD (2019 Feb 4). Cost-effectiveness of early cancer surveillance for patients with Li-Fraumeni syndrome. Pediatr Blood Cancer, e27629.
  4. Stenehjem DD, Au TH, Ngorsuraches S, Ma J, Bauer H, Wanishayakorn T, Nelson RS, Pfeiffer CM, Schwartz J, Korytowsky B, Oderda G, Brixner DI (2019 Jan 25). Immunotargeted therapy in melanoma: patient, provider preferences, and willingness to pay at an academic cancer center.LID - 10.1097/CMR.0000000000000572 [doi]. (Epub ahead of print) Melanoma Res.
  5. Kim K, Magness JW, Nelson R, Baron V, Brixner DI (2018 Dec). Clinical Utility of Pharmacogenetic Testing and a Clinical Decision Support Tool to Enhance the Identification of Drug Therapy Problems Through Medication Therapy Management in Polypharmacy Patients. J Manag Care Spec Pharm, 24(12), 1250-1259.
  6. Stenehjem DD, Au T, Sainski AM, Bauer H, Brown K, Lancaster J, Stevens V, Brixner DI (2018 Mar 7). Impact of a genetic counseling requirement prior to genetic testing. BMC Health Serv Res, 18(1), 165.
  7. Devine EB, Perfetto E, Pickard AS, Schumock GT, Segal JB, Cannon E, Gagnon JP, Brixner DI, Garrison LP, Murray MD (2018 Feb). Nine years of comparative effectiveness research education and training: initiative supported by the PhRMA Foundation. Journal of Comparative Effectiveness Research, 7(2), 167-175.
  8. Bellows BK, Sainski-Nguyen AM, Olsen CJ, Boklage SH, Charland S, Mitchell MP, Brixner DI (2017 Sep). Identification of Patients with Statin Intolerance in a Managed Care Plan: A Comparison of 2 Claims-Based Algorithms. J Manag Care Spec Pharm, 23(9), 926-934.
  9. Brixner DI, Stenehjem DD, Ulrich C (2016 Oct 1). Aspirin and Cancer Risk. JAMA Oncol, 2(10), 1370-1371.
  10. Unni SK, Schauerhamer MB, Deka R, Tyczynski JE, Fernandes AW, Stevens V, Brixner DI, Stenehjem DD (2016 Mar 22). BRCA testing, treatment patterns and survival in platinum-sensitive recurrent ovarian cancer - an observational cohort study. J Ovarian Res, 9, 18.
  11. Bress AP, King JB, Brixner D, Kielhorn A, Patel HK, Maya J, Lee VC, Biskupiak J, Munger M (2016 Feb). Pharmacotherapy Treatment Patterns, Outcomes, and Health Resource Utilization Among Patients with Heart Failure with Reduced Ejection Fraction at a U.S. Academic Medical Center. Pharmacotherapy, 36(2), 174-86.
  12. Stenehjem DD, Bellows BK, Yager KM, Jones J, Kaldate R, Siebert U, Brixner DI (2016 Feb). Cost-Utility of a Prognostic Test Guiding Adjuvant Chemotherapy Decisions in Early-Stage Non-Small Cell Lung Cancer. Oncologist, 21(2), 196-204.
  13. Rochau U, Vukicevic D, Schmidt S, Stenehjem D, Brixner D, Radich J, Gastl G, Siebert U (2015 Nov). COST-EFFECTIVENESS ANALYSIS ON STARTING PATIENTS WITH CHRONIC MYELOID LEUKEMIA ON A HIGHLY POTENT TYROSINE KINASE INHIBITOR AND EARLY SWITCHING TO IMATINIB. Value Health, 18(7), A462.
  14. Unni S, White K, Goodman M, Ye X, Mavros P, Bash LD, Brixner D (2015 Jun). Hypertension control and antihypertensive therapy in patients with chronic kidney disease. Am J Hypertens, 28(6), 814-22.
  15. Rochau U, Kluibenschaedl M, Stenehjem D, Kuan-Ling K, Radich J, Oderda G, Brixner D, Siebert U (2015). Effectiveness and Cost-Effectiveness of Sequential Treatment of Patients with Chronic Myeloid Leukemia in the United States: A Decision Analysis. Leuk Res Treatment, 2015, 982395.
  16. Holtorf AP, Palacios D, Brixner D (2014 Nov). Are Patient Reported Outcomes Relevant To Patients? Learnings From A Patient Advocate Survey. Value Health, 17(7), A517.
  17. McAdam-Marx C, Bellows BK, Unni S, Mukherjee J, Wygant G, Iloeje U, Liberman JN, Ye X, Bloom FJ, Brixner DI (2014 Nov). Determinants of glycaemic control in a practice setting: the role of weight loss and treatment adherence (The DELTA Study). Int J Clin Pract, 68(11), 1309-17.
  18. Rochau U, Kluibenschaedl M, Stenehjem D, Kuo KL, Oderda G, Brixner D, Siebert U (2014 Nov). Decision Analysis on the Cost-Effectiveness of Sequential Treatment Strategies for Patients with Chronic Myeloid Leukemia in the United States. Value Health, 17(7), A639.
  19. Tang DH, Warholak TL, Hines LE, Hurwitz J, Brown M, Taylor AM, Brixner D, Malone DC (2014 Sep-Oct). Evaluation of Pharmacy and Therapeutic (P&T) Committee member knowledge, attitudes and ability regarding the use of comparative effectiveness research (CER) in health care decision-making. Res Social Adm Pharm, 10(5), 768-80.
  20. Rochau U, Sroczynski G, Wolf D, Schmidt S, Conrads-Frank A, Jahn B, Saverno K, Brixner D, Radich J, Gastl G, Siebert U (2014 Aug). Medical decision analysis for first-line therapy of chronic myeloid leukemia. Leuk Lymphoma, 55(8), 1758-67.
  21. Stenehjem DD, Albright F, Kuo KL, Raimundo K, Bauer H, Shami PJ, Deininger MW, Chen L, Brixner DI (2014 Aug). Response monitoring, tolerability, and effectiveness of imatinib treatment for chronic myeloid leukemia in a retrospective research database. J Natl Compr Canc Netw, 12(8), 1113-21.
  22. McAdam-Marx C, Bellows BK, Unni S, Wygant G, Mukherjee J, Ye X, Brixner DI (2014 Jul). Impact of adherence and weight loss on glycemic control in patients with type 2 diabetes: cohort analyses of integrated medical record, pharmacy claims, and patient-reported data. J Manag Care Spec Pharm, 20(7), 691-700.
  23. Oderda GM, Shiozawa A, Walsh M, Hess K, Brixner DI, Feehan M, Akhras K (2014 May). Physician adherence to ACR gout treatment guidelines: perception versus practice. Postgrad Med, 126(3), 257-67.
  24. Saverno K, Gothe H, Schuessel K, Biskupiak J, Schulz M, Siebert U, Brixner D (2014 Mar). Consideration of international generic distribution policies on patient outcomes in the United States and Germany. Pharmazie, 69(3), 238-40.
  25. Chen SY, Lee YC, Alas V, Greene M, Brixner D (2014 Mar). Outcomes associated with nonconcordance to National Kidney Foundation guideline recommendations for oral antidiabetic drug treatments in patients with concomitant type 2 diabetes and chronic kidney disease. Endocr Pract, 20(3), 221-31.
  26. McAdam-Marx C, Mukherjee J, Bellows BK, Unni S, Ye X, Iloeje U, Brixner DI (2014 Mar). Evaluation of the relationship between weight change and glycemic control after initiation of antidiabetic therapy in patients with type 2 diabetes using electronic medical record data. Diabetes Res Clin Pract, 103(3), 402-11.
  27. Stenehjem DD, Yoo M, Unni SK, Singhal M, Bauer H, Saverno K, Quah C, Masaquel A, Brixner DI (2014). Assessment of HER2 testing patterns, HER2+ disease, and the utilization of HER2-directed therapy in early breast cancer. Breast Cancer (Dove Med Press), 6, 169-77.
  28. Villa L, Warholak TL, Hines LE, Taylor AM, Brown M, Hurwitz J, Brixner D, Malone DC (2013 Nov-Dec). Health care decision makers' use of comparative effectiveness research: report from a series of focus groups. J Manag Care Pharm, 19(9), 745-54.
  29. Saverno K, Neu, G, Schmidt S, Wolf D, Conrads-Frank A, Jahn B, Sroczynski G, Brixner, DI (). Medical Decision Analysis for the First-line Therapy of Chronic Myeloid Leukemia. Leuk Lymphoma.
  30. Dhamane A, Martin B, Brixner DI, Hudson T, Said Q (). Metabolic Monitoring of Patients Prescribed Second-Generation Antipsychotics. Journal of Psychiatric Practice, 19(5), 1-15.
  31. Goodman MJ, Ghate SR, Mavros P, Sen S, Marcus RL, Joy E, Brixner DI (2013 Sep). Development of a practical screening tool to predict low muscle mass using NHANES 1999-2004. Med Image Comput Comput Assist Interv, 4(3), 187-97.
  32. Dhamane A, Martin, B, Brixner DI, Hudson T, Said Q (). Metabolic Monitoring of Patients Prescribed Second Generation Antipsychoitic. Journal of Psychiatric Practice, 19(5), 1-15.
  33. Brixner, DI, Bron M, Bellows BK, Ye X, Yu J, Raparla S, Oderda GM (). Evaluation of Cardiovascular Risk Factors, Events and Costs Across Four BMI Categories. Obesity (Silver Spring), 21(6), 1284-92.
  34. Goodman MJ, Ghate SR, Mavros P, Sen S, Marcus RL, Joy E, Brixner DI (). Development of a Practical Screening Tool to Predict Low Muscle Mass Using NHANES 1999-2004. J Cachexia Sarcopenia Muscle.
  35. Stanford JB, Martin JC, Gibson M, Birsall E, Brixner DI (). Use of Clomiphene Citrate in the University of Utah Community Clinics. J Reprod Med, 58(5-6), 229-33.
  36. Stanford JB, Martin JC, Gibson M, Birdsall E, Brixner DI (2013 May-Jun). Use of clomiphene citrate in the University of Utah Community Clinics. J Reprod Med, 58(5-6), 229-33.
  37. Goodman MJ, Brixner DI (). New Therapies for Treating Down Syndrome Require Quality of Life Measurement. Am J Med Genet A, 1(4), 639-41.
  38. Ghate SR, Porucznik CA, Said Q, Hashibe M, Joy E, Brixner DI (2013 Mar). Association between second-generation antipsychotics and changes in body mass index in adolescents. J Adolesc Health, 52(3), 336-43.
  39. Ghate S, Porucznik C, Said Q, Hashibe M, Joy E, Brixner DI (). Association Between Second Generation Antipsychotics and Changes in Body Mass Index in Adolescents. J Adolesc Health, 52(3), 336-343.
  40. Ghate SR, Porucznik CA, Said Q, Hashibe M, Joy E, Brixner DI (). Association Between Second-generation Antipsychotics and Changes in Body Mass Index in Adolescents. J Adolesc Health, 52(3), 336-43.
  41. Chen Sy, Lee YC, Alas V, Greene M, Brixner DI (). Outcomes Associated with Concordance of Oral Antidiabetic Drug Treatments to Prescribing Information in Patients With Type 2 Diabetes Mellitis and Chronic Kidney Disease. Journal of Medical Economics, 16(5), 586-95.
  42. Chen SY, Lee YC, Alas V, Greene M, Brixner D (2013). Outcomes associated with concordance of oral antidiabetic drug treatments to prescribing information in patients with type 2 diabetes mellitus and chronic kidney disease. J Med Econ, 16(5), 586-95.
  43. Holtorf A, Brixner DI, Bellows B, Keskinaslan A, Dye J, Oderda G (). Current and Future Use of HEOR Data in Healthcare Decision-Making in the United States and in Emerging Markets. American Health & Drug Benefits, 5(7).
  44. Holtorf AP, Brixner D, Bellows B, Keskinaslan A, Dye J, Oderda G (2012 Nov). Current and Future Use of HEOR Data in Healthcare Decision-Making in the United States and in Emerging Markets. American Health & Drug Benefits, 5(7), 428-38.
  45. Lau YS, Blouin R, Brixner DI, Crismon L, Cutler S, Ho R, Jusko W, Nahata M, Sorkness C, Torchilin VP, Wu-Pong S (). Report of the 2011-2012 AACP Special Advisory Committee on Research and Graduate Education. Am J Pharm Educ, 76(8), S14.
  46. Ghate SR, Porucznik CA, Said Q, Hashibe M, Joy E, Brixner DI (2012 Sep). Predictors of metabolic parameter monitoring in adolescents on antipsychotics in a primary care setting. Ment Health Fam Med, 9(3), 137-48.
  47. Saverno KR, Rochau U, Stenehjem DD, Morley K, Siebert U, Brixner DI (). Application of Decision-Analytic Models in Personalized Medicine for CML Treatment Decisions Made by Payers, Providers, and Patients. J Manag Care Pharm, 18(6), 457-463.
  48. Saverno KR, Rochau U, Stenehjem DD, Morley K, Siebert U, Brixner DI (2012 Jul-Aug). Application of decision-analytic models in personalized medicine for CML treatment decisions made by payers, providers, and patients. J Manag Care Pharm, 18(6), 457-63.
  49. Brixner DI, Watkins J, Oderda G, Sifford-Wilson S, Biskupiak J, Dunn J, Holtorf A (). This Drug May Work, But Is It Worth the Cost? Can Comparative Effectiveness Research Help Tame Rising Health Cost? Suppl. J Manag Care Pharm, June 18(5), S6-19.
  50. Goodman MJ, Durkin M, Forlenza J, Ye X, Brixner DI (2012 Jun). Assessing adherence-based quality measures in epilepsy. Int J Qual Health Care, 24(3), 293-300.
  51. Brixner DI (2012 Jun). Introduction. Can comparative effectiveness research help tame rising health care costs? J Manag Care Pharm, 18(5 Supp A), S05.
  52. Brixner DI, Watkins JB (2012 Jun). Can CER be an effective tool for change in the development and assessment of new drugs and technologies? J Manag Care Pharm, 18(5 Supp A), S06-11.
  53. Brixner DI (). This Drug May Work, But Is It Worth the Cost? Can Comparative Effectiveness Research Help Tame Rising Health Cost? [Introduction] Suppl. J Manag Care Pharm, Jun 18(5), S5.
  54. Brixner DI, Oderda G (2012 May). It is important to distinguish CER from patient-centered outcomes research. Introduction. J Manag Care Pharm, 18(4 Suppl A), S3-4.
  55. Brixner DI, Oderda G (). Three Perspectives on the Impact of Comparative Effectiveness Research on Decision Making. [Introduction] Suppl. J Manag Care Pharm, May 18(4a), S3-4.
  56. Brixner DI, Oderda G, Mohr P, Dubois R, Cannon HE (). Three Perspectives on the Impact of Comparative Effectiveness Research on Decision Making. Suppl. J Manag Care Pharm, May 18(4a), S5-17.
  57. Marcus RL, Brixner DI, Ghate S, Lastayo P (2012). Fat Modulates the Relationship between Sarcopenia and Physical Function in Nonobese Older Adults. Curr Gerontol Geriatr Res, 2012, 216185.
  58. Ghate SR, Biskupiak J, Ye X, Kwong WJ, Brixner DI (2011 Nov). All-cause and bleeding-related health care costs in warfarin-treated patients with atrial fibrillation. J Manag Care Pharm, 17(9), 672-84.
  59. McAdam-Marx C, McGarry LJ, Hane CA, Biskupiak J, Deniz B, Brixner DI (2011 Sep). All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective. J Manag Care Pharm, 17(7), 531-46.
  60. Kempf J, Buysman E, Brixner D (2011 Sep). Health Resource Utilization and Direct Costs Associated with Angina for Patients with Coronary Artery Disease in a US Managed Care Setting. American Health & Drug Benefits, 4(6), 353-61.
  61. Ghate SR, Biskupiak JE, Ye X, Hagan M, Kwong WJ, Fox ES, Brixner DI (2011 Jun). Hemorrhagic and thrombotic events associated with generic substitution of warfarin in patients with atrial fibrillation: a retrospective analysis. Ann Pharmacother, 45(6), 701-12.
  62. LaFleur J, McAdam-Marx C, Alder SS, Sheng X, Asche CV, Nebeker J, Brixner DI, Silverman SL (2011 Mar). Clinical risk factors for fracture among postmenopausal patients at risk for fracture: a historical cohort study using electronic medical record data. J Bone Miner Metab, 29(2), 193-200.
  63. McAdam-Marx C, Bouchard J, Aagren M, Conner C, Brixner DI (2011 Jan). Concurrent control of blood glucose, body mass, and blood pressure in patients with type 2 diabetes: an analysis of data from electronic medical records. Clin Ther, 33(1), 110-20.
  64. Kempf J, Buysman E, Brixner DI (). Health Resource Utilization and Direct Costs Associated with Angina for Patients with Coronary Artery Disease in a US Managed Care Setting. American Health & Drug Benefits.
  65. Nelson RE, McAdam-Marx C, Evans ML, Ward R, Campbell B, Brixner DI, LaFleur J (). Patent extension policy for paediatric indications: an evaluation of the impact within three drug classes in a state Medicaid program. Appl Health Econ Health Policy, 1;9(3), 171-81.
  66. Yu J, Smith KJ, Brixner DI (2010 Aug). Cost effectiveness of pharmacotherapy for the prevention of migraine: a Markov model application. CNS Drugs, 24(8), 695-712.
  67. Brixner DI, McAdam-Marx C, Ye X, Lau H, Munger MA (2010 Aug). Assessment of time to follow-up visits in newly-treated hypertensive patients using an electronic medical record database. Curr Med Res Opin, 26(8), 1881-91.
  68. McAdam-Marx C, Gaebler JA, Bellows BK, Brixner DI (2010 Jun). Contemporary management of patients with Type 2 diabetes. Expert Rev Cardiovasc Ther, 8(6), 767-70.
  69. Said Q, Marx CM, Schwartz JS, Ben-Joseph R, Brixner DI (2010 Mar-Apr). Impact of body mass index on the incidence of cardiometabolic risk factors in ambulatory care settings over 5 years or more. Value Health, 13(2), 265-72.
  70. McAdam-Marx C, Yu J, Bouchard J, Aagren M, Brixner DI (2010 Jan). Comparison of daily insulin dose and other antidiabetic medications usage for type 2 diabetes patients treated with an analog basal insulin. Curr Med Res Opin, 26(1), 191-201.
  71. McAdam-Marx C, Bouchard J, Aagren M, Nelson R, Brixner D (2010 Jan). Analysis of glycaemic control and weight change in patients initiated with human or analog insulin in an US ambulatory care setting. Diabetes, Obesity and Metabolism Online, 12(1), 54-64.
  72. McAdam-Marx C, Field RI, Metraux S, Moelter ST, Brixner DI (2010 Jan). Physician utilization by insurance type among youth with type 2 diabetes. Am J Manag Care, 16(1), 55-64.
  73. Brixner DI, Ye X, Chu TC, Blumentals WA, Hassanein TI (2009 Dec 15). Treatment persistence in and cost of therapy for patients with chronic hepatitis C: Peginterferon alfa-2a plus ribavirin versus peginterferon alfa-2b plus ribavirin. Am J Health Syst Pharm, 66(24), 2171-8.
  74. Brixner DI, McAdam-Marx C, Ye X, Boye KS, Nielsen LL, Wintle M, Misurski D, Fabunmi R (2009 Dec). Six-month outcomes on A1C and cardiovascular risk factors in patients with type 2 diabetes treated with exenatide in an ambulatory care setting. Diabetes, Obesity and Metabolism Online, 11(12), 1122-30.
  75. McAdam-Marx C, Ye X, Sung JC, Brixner DI, Kahler KH (2009 May). Results of a retrospective, observational pilot study using electronic medical records to assess the prevalence and characteristics of patients with resistant hypertension in an ambulatory care setting. Clin Ther, 31(5), 1116-23.
  76. Kane SV, Accortt NA, Magowan S, Brixner D (2009 Apr 15). Predictors of persistence with 5-aminosalicylic acid therapy for ulcerative colitis. Aliment Pharmacol Ther, 29(8), 855-62.
  77. Brixner DI, Holtorf AP, Neumann PJ, Malone DC, Watkins JB (2009 Apr). Standardizing quality assessment of observational studies for decision making in health care. J Manag Care Pharm, 15(3), 275-83.
  78. Smith MD, Drummond M, Brixner D (2009 Mar). Moving the QALY forward: rationale for change. Value Health, 12 Suppl 1, S1-4.
  79. McAdam-Marx C, Brixner DI, Metraux S, Moelter S, Field R (). Antidiabetic Treatment and A1C Testing in Youth with Type 2 Diabetes in an Ambulatory Care Setting. Diabetes, 58(S1), A514.
  80. Brixner D, Ghate SR, McAdam-Marx C, Ben-Joseph R, Said Q (2008 Oct). Association between cardiometabolic risk factors and body mass index based on diagnosis and treatment codes in an electronic medical record database. J Manag Care Pharm, 14(8), 756-67.
  81. Brixner DI, Jackson KC 2nd, Sheng X, Nelson RE, Keskinaslan A (2008 Sep). Assessment of adherence, persistence, and costs among valsartan and hydrochlorothiazide retrospective cohorts in free-and fixed-dose combinations. Curr Med Res Opin, 24(9), 2597-607.
  82. Hendlish SK, Horowicz-Mehler NC, Brixner DI, Stern LS, Doyle JJ, Chang J, Hagan M (2008 Jul). Contraceptive and noncontraceptive benefits of the LNG-IUS in a vertically integrated HMO. Contraception, 78(1), 36-41.
  83. Joanne L, Leslie F, Brixner DI (2008 May). Trends in pharmaceutical expenditures: the impact on drug benefit design. American Health & Drug Benefits, 1(4), 29-34.
  84. Murphy PA, Brixner D (2008 Apr). Hormonal contraceptive discontinuation patterns according to formulation: investigation of associations in an administrative claims database. Contraception, 77(4), 257-63.
  85. Holtorf AP, Watkins JB, Mullins CD, Brixner D (2008 Apr). Incorporating observational data into the formulary decision-making process--summary of a roundtable discussion. J Manag Care Pharm, 14(3), 302-8.
  86. Said Q, Gutterman EM, Kim MS, Firth SD, Whitehead R, Brixner D (2008 Apr). Somnolence effects of antipsychotic medications and the risk of unintentional injury. Pharmacoepidemiol Drug Saf, 17(4), 354-64.
  87. Hassanein T, Ye X, Chu TC, Brixner DI (). Clinical and Persistency Outcomes in Hepatitis C Patients Treated with Peginterferon Alfa-2a or Peginterferon Alfa-2b Plus Ribavirin. Gastroenterology, Supp1, 134(4), A-833.
  88. LaFleur J, McAdam-Marx C, Kirkness C, Brixner DI (). Clinical Risk Factors for Fracture in Post-Menopausal Osteoporotic Women: a Review of the Recent Literature. Ann Pharmacother, 42(3), 375-86.
  89. Hassanein T, Ye X, Blumentals WA, Brixner DI (). Clinical and Persistency Outcomes in Hepatitis C Patients Treated with Peginterferon Alfa-2a or Peginterferon Alfa-2b Plus Ribavirin. J Hepatol, Supp2, 48(2), S295-6.
  90. Asche C, Said Q, Joish V, Hall CO, Brixner D (2008). Assessment of COPD-related outcomes via a national electronic medical record database. Int J Chron Obstruct Pulmon Dis, 3(2), 323-6.
  91. Brixner DI, Lenhart G, Young DC, Samuelson WM (2007 Nov). The effect of fixed combination of fluticasone and salmeterol on asthma drug utilization, asthma drug cost, and episodes of asthma exacerbations. Curr Med Res Opin, 23(11), 2887-95.
  92. Nickman NA, Biskupiak J, Creekmore F, Shah H, Brixner DI (2007 Nov 1). Antiplatelet medication management in patients hospitalized with ischemic stroke. Am J Health Syst Pharm, 64(21), 2250-6.
  93. Brixner DI (2007 Jul). Prevalence and burden of migraine and the impact on managed care. Manag Care, 16(7 Suppl 7), 2-3; discussion 15-7.
  94. Brixner DI, Joish VN, Odera GM, Avey SG, Hanson DM, Cannon HE (2007 Jun). Effects of benefit design change across 5 disease states. Am J Manag Care, 13(6 Pt 2), 370-6.
  95. Jackson KC 2nd, Nahoopii R, Said Q, Dirani R, Brixner D (2007 Apr). An employer-based cost-benefit analysis of a novel pharmacotherapy agent for smoking cessation. J Occup Environ Med, 49(4), 453-60.
  96. Ho MJ, Kirkness C, Brixner DI (). Problem Based Learning in Pharmacy Management. J Pharm Teach, 49(4), 453-60.
  97. Brixner DI, Said Q, Kirkness C, Oberg B, Ben-Joseph R Oderda G (). Assessment of Cardiometabolic Risk Factors in a National Primary Care Electronic Health Record Database. Value Health, 10(1), S29-36.
  98. Brixner DI, Rubin DT, Sewitch MJ (). The Complexity of Compliance and Persistence in Ulcerative Colitis. Gastroenterol Hepatol (N Y), Supp 28, 3(9), S1-10.
  99. Creekmore FM, Oderda GM, Pendleton RC, Brixner DI (2006 Oct). Incidence and economic implications of heparin-induced thrombocytopenia in medical patients receiving prophylaxis for venous thromboembolism. Pharmacotherapy, 26(10), 1438-45.
  100. Pichichero ME, Brixner DI (2006 Aug). Rethinking the total cost of care in AOM and ABS: The impact of improved diagnostic accuracy and antibiotic treatment where high efficacy and adherence are achievable. Am J Manag Care, 12(10 Suppl), S283-91.
  101. LaFleur J, Thompson CJ, Joish VN, Charland SL, Oderda GM, Brixner DI (2006 Jul-Aug). Adherence and persistence with single-dosage form extended-release niacin/lovastatin compared with statins alone or in combination with extended-release niacin. Ann Pharmacother, 40(7-8), 1274-9.
  102. Brixner D (2006 May). Managing osteoporosis in a managed care population. Am J Manag Care, 12(7 Suppl), S199-202.
  103. Brixner D (2006 May). Assessment of the prevalence and costs of osteoporosis treatment options in a real-world setting. Am J Manag Care, 12(7 Suppl), S191-8.
  104. Brixner DI, Said Q, Corey-Lisle PK, Tuomari AV, Litalien GJ, Stockdale W, Oderda GM (2006 Apr). Naturalistic impact of second-generation antipsychotics on weight gain. Ann Pharmacother, 40(4), 626-32.
  105. Brixner DI (2006 Apr). The case against excessive cost sharing. Am J Manag Care, 12(6 Suppl), S162-4; discussion S167-72; quiz S173-6.
  106. Brixner DI, Oderda GM, Nickman NA, Beveridge R, Jorgenson JA (2006 Mar). Documentation of chemotherapy infusion preparation costs in academic- and community-based oncology practices. J Natl Compr Canc Netw, 4(3), 197-208.
  107. Biskupiak JE, Brixner DI, Howard K, Oderda GM (2006). Gastrointestinal complications of over-the-counter nonsteroidal antiinflammatory drugs. J Pain Palliat Care Pharmacother, 20(3), 7-14.
  108. Gerbino PP, Brixner DI, Sbarbaro J, Nicolau D (2006, In Press). Appropriate Initial antibiotic therapy in the treatment of community-acquired respiratory tract infections. Manag Care Interface.
  109. Joish VN, Brady E, Stockdale W, Brixner DI, Dirani R (2006). Evaluating Diagnosis and Treatment Patterns of COPD in Primary Care. Treat Respir Med, 5(4), 283-93.
  110. Brixner DI, Oderda GM, Roland CL, Rublee DA (2006). Opioid expenditures and utilization in the Medicaid system. J Pain Palliat Care Pharmacother, 20(1), 5-13.
  111. Trost LF 3rd, Wender RC, Suter CC, Von Worley AM, Brixner DI, Rosenberg JH, Gunter MJ (2005 Dec). Management of epilepsy in adults. Treatment guidelines. Postgrad Med, 118(6), 29-33.
  112. Gerbino PP, Brixner D, Sbarbaro J, Nicolau D (2005 Dec). Appropriate antibiotic therapy for community-acquired respiratory tract infections. Manag Care Interface, 18(12), 41-8.
  113. Brixner DI, Ho MJ (2005 Nov). Clinical, humanistic, and economic outcomes of gout. Am J Manag Care, 11(15 Suppl), S459-64; quiz S465-8.
  114. Brixner DI (2005 Aug). Improving acute otitis media outcomes through proper antibiotic use and adherence. Am J Manag Care, 11(6 Suppl), S202-10.
  115. Brixner DI (2005, August). Managing the continuum of treatment: modeling the economic impact of treating Diabetes. J Manag Care Pharm, 11((6, S-b)), S19-S22.
  116. Brixner DI (2005 Aug). Managing the continuum of treatment: modeling the economic impact of treating diabetes. J Manag Care Pharm, 11(6 Suppl B), S19-22.
  117. LaFleur J, Thompson C, Ho M, Stockdale W, Charland SL, Oderda G, Brixner DI (2005 July). Cost analysis of combination vs. single dosage lipid lowering. Hosp Formul, 40(7), 233-234.
  118. Joish VN, Donaldson G, Stockdale W, Oderda GM, Crawley J, Sasane R, Joshua-Gotlib S, Brixner DI (2005 Apr). The economic impact of GERD and PUD: examination of direct and indirect costs using a large integrated employer claims database. Curr Med Res Opin, 21(4), 535-44.
  119. Sullivan PW, Valuck R, Brixner DI, Armstrong EP (2005). A Pharmacoeconomic Model for Making Value-Based Decisions About Serotonin Reuptake Inhibitors. P T, 30(2), 96-106.
  120. Brixner DI, Joish VN, Oderda GM, Stockdale WA, Avey S, Hanson DM, Cannon HE (2005, In Press). Impact of benefit change on drug use behaviors and healthcare costs in an integrated healthcare system. J Manag Care Pharm.
  121. Brixner DI, Paladino JA, Asche CV (2005, In Press). Economic value of telithromycin versus clarithromycin in the treatment of community-acquired pneumonia. J Manag Care Pharm.
  122. LaFleur J, Thompson C, Joish VN, Charland S, Oderda GM, Brixner DI (2005, In Press). Compliance and cost of therapy with single-dosage form extended-release Niacin/Lovastatin compared to statins alone or in combination with extended release Niacin. Ann Pharmacother.
  123. Brixner DI, Oderda GM, Nickman NA, Servatius D, Lambert A, Bancroft F, Bretzel R, Beveridge R, Vermulen L, Lentz S (2005, In Press). Documentation of pharmacy cost in the preparation of chemotherapy infusions in academic and community-based oncology practices. J Natl Compr Canc Netw.
  124. Brixner DI, Joish VN, Oderda GM, Stockdale WA, Avey S, Hanson D, Cannon E (2005, In Progress). Impact of prescription copay increases on patient behavior and costs in an integrated healthcare system. J Manag Care Pharm.
  125. Brixner DI, Said Q, Tuomari V, LItalien GJ, Corey-Lisle PK, Stockdale WA, Oderda GM (2005, In Press). Real world impact of second generation antipsychotics on weight gain. Ann Pharmacother.
  126. Gunter MJ, Worley AV, Carter S, Gregory C, Brixner DI (2004 Winter). Impact of seizure disorder disease management program on patient-reported quality of life. Dis Manag, 7(4), 333-347.
  127. Gunter MJ, Brixner D, von Worley A, Carter S, Gregory C (2004 Winter). Impact of a seizure disorder disease management program on patient-reported quality of life. Dis Manag, 7(4), 333-47.
  128. Brixner DI, Brandes JL (2004 Aug). Migraine matters: the role of triptans in relieving the burden in managed care. J Manag Care Pharm, 10(4 Suppl B), S2-12; quiz S13-6.
  129. Brixner DI (2004 May). Standardizing managed care formulary submissions: the AMCP format. Manag Care, 13(5), 14-17.
  130. Kane S, Borisov NN, Brixner DI (). Pharmacoeconomic Evaluation of Gastrointestinal Tract Events During Treatment with Resedronate or Alendronate: a Retrospective Cohort Study. Am J Manag Care, 10(7), S216-26.
  131. Joish VN, Brixner DI (2004). Back pain and productivity: measuring worker productivity from an employer's perspective. J Pain Palliat Care Pharmacother, 18(2), 79-85.
  132. Briggs DD, Brixner DI, Cannon HE, George DL (2004). Overview of chronic obstructive pulmonary disease: new approaches to patient management in managed care systems. J Manag Care Pharm, 10(4 S-a), S2-10.
  133. Brandes JL, Brixner DI (2004). Migraine Matters: The role of triptans in relieving the burden in management care. J Manag Care Pharm, (10 (4,S-b)), S2-12.
  134. Ho MJ, Joish VN, LaFleur J, Christensen RL, Brixner DI (2004). Pharmacoeconomic Analysis of Oral Triptans. Formulary, 39, 356-357.
  135. Kane S, Borisov NN, Brixner DI (2004). Pharmacoeconomic evaluation of gastrointestinal tract events during treatment with resedronate or alendronate: a retrospective cohort study. Am J Manag Care, 10(7), S216-226.
  136. Vermeulen LC, Windisch PA, Rydman RJ, Bruskiewitz RH, Brixner DI, Vlasses PH (2002). Using a multihospital systems framework to evaluate and establish drug use policy. J Med Syst, 24(4), 235-246.
  137. Clouse J, Gagnon JP, Boyer G, Brixner DI, Clancy C, De Lissovoy G, Morris L, Neumann P, Robinow A, Sullivan S (). Panel 5: Application of Healthcare Intervention Economic Evaluations in Healthcare Decision-Making. Value Health, March 2(2), 92-8.
  138. Kuehl M, Brixner DI, Broom AD, Avery TL, Blakley RL (1998). Cytotoxicity uptake, polyglutamate formation, and antileukemic effects of 8-deaza analogues of methotrexate and aminopterin in mice. Cancer Res, 48((6)), 1481-8.
  139. Wilson M, Patwell J, Shoheiber O, Eicher J, Brixner DI, et-al (1998). Clinical and economic implications of drug utilization patterns in the treatment of hypertension with ACE inhibitors and calcium channel blockers in a managed care setting. J Manag Care Pharm, 4(1), 194-202.
  140. Okano GJ, Rascati KL, Wilson JP, Remund DD, Grabenstein JD, Brixner DI (1997 Nov-Dec). Patterns of antihypertensive use among patients in the US Department of Defense database initially prescribed an angiotensin-converting enzyme inhibitor or calcium channel blocker. Clin Ther, 19(6), 1433-45; discussion 1424-5.
  141. Brixner DI, Bull SA (1997 Jun). The challenge of integrating monoclonal antibodies into the current healthcare system. Am J Manag Care, 3(6), 903-11.
  142. Brixner DI (1996 February). Pharmacoeconomics and Outcomes Research in the Pharmaceutical Industry. J Manag Care Pharm.
  143. Brixner DI (1994 Nov). A decision analysis model in the evaluation of NSAIDs in a managed care setting: a case study. Med Interface, 7(11), 145-50.
  144. Brixner DI, Dugowson CE (1994). Utilization Evaluation of NSAIDS in a Managed Care Setting: A Case Study. Medical Interface, November.
  145. Rao RN, Brixner DI, Srinivasan A, Kasina S, Vanderheyden JL, Wester DW, Fritzberg AR (1991). Synthesis and Characterization of Diamide Dithiol Complexes of Technetium (V) and Rhenium (V). Assignment of Stereochemistry of the Chelate Epimers by NMR Spectroscopy. Int J Rad Appl Instrum [A], 42, 525.
  146. Rao TN, Brixner DI, Srinivasan A, Kisina S, Vanderheyden JL, Wester DW, Fritzberg AR (). International Journal of Radiation Applications and Instrumentation Part A. Applied Radiation and Isotopes. Appl Radiat Isot, 42(6), 525-30.
  147. Brixner DI (1991). Biotechnology: Impact on Pharmacists. Pharm Times, 39.
  148. Brixner DI (1991). Monoclonal Antibodies: From the Research Lab to the Pharmacy. J Pharm Pract, 4(1), 94.
  149. Kuehl M, Brixner DI, Broom AD, Avery TL, Blakley RL (1988 Mar 15). Cytotoxicity, uptake, polyglutamate formation, and antileukemic effects of 8-deaza analogues of methotrexate and aminopterin in mice. Cancer Res, 48(6), 1481-8.
  150. Bayomi SM, Brixner DI, Eissa HM, Broom AD (1988). An N10-Propargylated Derivative of a Multisubstrate Inhibitor of Thymidylate Synthetase. Nucleosides Nucleotides, 7(1), 103.
  151. Brixner DI, Ueda T, Cheng YC, Hynes JB, Broom AD (1987 Apr). Folate analogues as inhibitors of thymidylate synthase. J Med Chem, 30(4), 675-8.
  152. Beres J, Lee Y, Brixner DI, Olsen JI, Schweizer MP (1986). Alkaline Degradation of 1,3-Di-(2-hydroxyethyl) adensine 3',5'-Cyclic Phospate. Nucleosides Nucleotides, 5(1), 1.
  153. Goodman, M, Brixner DI (). Down Syndrome Therapeutic Consortium. Am J Med Genet.
  154. Saverno K, Gothe H, Schuessel K, Biskupiak JE, Schulz M, Siebert U, Brixner DI (). Consideration of International Generic Distribution Policies on Patient Outcomes in the United States and Germany. Pharmazie.
  155. Schwarzer R, Rochau U, Saverno K, Jahn B, Bornschein B, Muehlberger N, Flatscher-Thoeni M, Schnell-Inderst P, Sroczynski G, Lackner M, Schall I, Hebborn A, Pugner K, Fehervari A, Brixner DI, Siebert U (). Systematic overview of cost-effectiveness thresholds in ten countries across four continents with a special focus on personalized cancer medicine. Per Med.

Review

  1. Oderda GM, Lawless GD, Wright GC, Nussbaum SR, Elder R, Kim K, Brixner DI (2018 Jul 1). The potential impact of monitoring disease activity biomarkers on rheumatoid arthritis outcomes and costs. [Review]. Per Med, 15(4), 291-301.
  2. Gothe H, Schall I, Saverno K, Mitrovic M, Luzak A, Brixner D, Siebert U (2015 Aug). The Impact of Generic Substitution on Health and Economic Outcomes: A Systematic Review. [Review]. Appl Health Econ Health Policy, 13 Suppl 1, S21-33.
  3. Kalo Z, Holtorf AP, Alfonso-Cristancho R, Shen J, Agh T, Inotai A, Brixner D (2015 Mar). Need for multicriteria evaluation of generic drug policies. [Review]. Value Health, 18(2), 346-51.
  4. Brixner DI, McAdam-Marx C (2008 Nov). Cost-effectiveness of insulin analogs. [Review]. Am J Manag Care, 14(11), 766-75.
  5. LaFleur J, McAdam-Marx C, Kirkness C, Brixner DI (2008 Mar). Clinical risk factors for fracture in postmenopausal osteoporotic women: a review of the recent literature. [Review]. Ann Pharmacother, 42(3), 375-86.
  6. Muszbek N, Brixner D, Benedict A, Keskinaslan A, Khan ZM (2008 Feb). The economic consequences of noncompliance in cardiovascular disease and related conditions: a literature review. [Review]. Int J Clin Pract, 62(2), 338-51.
  7. Kane SV, Brixner D, Rubin DT, Sewitch MJ (2008 Jan). The challenge of compliance and persistence: focus on ulcerative colitis. [Review]. J Manag Care Pharm, 14(1 Suppl A), s2-12; quiz s13-5.
  8. Pichichero ME, Brixner DI (2006 Aug). A review of recommended antibiotic therapies with impact on outcomes in acute otitis media and acute bacterial sinusitis. [Review]. Am J Manag Care, 12(10 Suppl), S292-302.
  9. Brixner DI (2004 Oct). Clinical and economic outcomes in the treatment of lower respiratory tract infections. [Review]. Am J Manag Care, 10(12 Suppl), S400-7.

Book Chapter

  1. Vaillancourt A, Chisholm-Burns M, Brixner, DI (). Creating and Identifying Desirable Workplaces. In Pharmacy Leadership, Marketing and Finance (2nd edition, Chapter 23, pp. 400-415). Jones and Bartlett Learning.
  2. Holtorf A, Rinde H, Rupprecht F, Alder H, Brixner DI (). The Economic Impact of Bariatric Surgery. In Chih-Kun Huang (Ed.), Advanced Bariatric and Metabolic Surgery (pp. 61-86). Croatia: Intech.
  3. Holtorf A, Rinde H, Rupprecht F, Alder H, Brixner D (). The Economic Impact of Bariatric Surgery in "Advanced Bariatric and Metabolic Surgery" (Chih-Kun Huang). Croatia: Intech.
  4. Brixner DI, Joish VN, Biskupiak JE, Shah H (). Pharmacoeconomic Research in Managed Care. In Managed Care and Pharmacoeconomics (Robert Navarro) (2nd edition). Jones and Bartlett Publishers.
  5. Brixner DI, Joish VN, Biskupiak JE, Shah H (2004). Pharmacoeconomic Research in Managed Care in "Managed Care and Pharmacoeconomics". In Robert Navarro (Ed.) (2nd edition). New York: Aspen Publishers.
  6. Brixner DI, Szeinbach S, Shah H, Mehta S, Ryu S (1999). Pharmacoeconomic Research in Managed Care. In Navarro R (Ed.), Managed Care and Pharmacoeconomics. New York: Aspen Publishers.
  7. Brixner DI, Pochtar P, Talbott JE (1997). Pharmacoeconomics in Making Sense of Managed Care Volume II: Strategic Positioning". In Miller KA, Miller EK (Eds.). San Francisco, CA: Jossey-Bass Publishers.
  8. Brixner DI (1993). Biotechnology Products: An Overview. In John M. Pezzuto, Michael E. Johnson, Henri R. Manassee (Eds.), Biotechnology and Pharmacy. New York: Chapman and Hall Publishers.

Conference Proceedings

  1. Drummond M, Brixner D, Gold M, Kind P, McGuire A, Nord E (2009 Mar). Toward a consensus on the QALY. Utah Special Educator, United States, 12 Suppl 1, S31-5.

Commentary

  1. Brixner, DI (). Commentary: Payer Perspective in Evaluating Diabetic Medications for Glycemic Control in type 2 Diabetes. Supplement. J Manag Care Pharm, Jan/Feb 18(1a), S15.
  2. Brixner, DI (). Commentary: AHRQ's comparative effectiveness research on oral medications for type 2 diabetes: a summary of the key findings. J Manag Care Pharm, Jan-Feb 18(Suppl A), 1-22.
  3. Brixner DI (). Clinical Commentary 2: The Payer Perspective on Evaluating Add-On Therapy
    to Standard Medical Therapy in Managing Stable Ischemic Heart Disease. J Manag Care Pharm, 17(5), S9.
  4. Brixner, DI (). Clinical Commentary 2: The Payer Perspective on ACEIs, ARBs, and DRIs for Treating Essential Hypertension. Suppl. J Manag Care Pharm, October 17(8), S9.

Editorial

  1. Goodman MJ, Brixner DI (2013 Apr). New therapies for treating Down syndrome require quality of life measurement. Med Image Comput Comput Assist Interv, 161A(4), 639-41.

Letter

  1. Ruble JH, Brixner DI (2016 Feb 16). Pharmacy Expenditures for Children With Serious Chronic Illness [Letter to the editor]. JAMA, 315(7), 706.
  2. McAdam-Marx C, Ye X, Brixner DI, Fabunmi R, Wintle M, Boye KS, Misurski D, Nielsen LL (2009 Dec). A1C and weight outcomes at 18 months in patients with type 2 diabetes treated with exenatide in an ambulatory care setting [Letter to the editor]. Diabetes, Obesity and Metabolism Online, 11(12), 1173-4.
  3. Jackson KC 2nd, Sheng X, Nelson RE, Keskinaslan A, Brixner DI (2008 Aug). Adherence with multiple-combination antihypertensive pharmacotherapies in a US managed care database [Letter to the editor]. Clin Ther, 30(8), 1558-63.
  4. Asche CV, Brixner DI, Oderda GM (2005 May). Has the cost-effectiveness of Xolair (omalizumab) been underestimated? [Letter to the editor]. J Allergy Clin Immunol, 115(5), 1095; author reply 1095-6.

Abstract

  1. Biskupiak J, Ghate S, Jiao T, Brixner DI (). Cost implications of formulary decisions on oral anticoagulants in nonvalvular atrial fibrillation [Abstract]. Journal of Managed Care Pharmacy, 19(9), 789-98.
  2. Villa L, Warholak T, Hines L, Taylor A, Brown M, Hurwitz J, Brixner DI, Malone D (). Health Care Decision Makers’ Use of Comparative Effectiveness Research: Report from a Series of Focus Groups [Abstract]. Journal of Managed Care Pharmacy, 19(9), 745-54.
  3. Brixner DI, Watkins JB (). Can CER Be an Effective Tool for Change in the Development and Assessment of New Drugs and Technologies? [Abstract]. J Manag Care Pharm, 5 Supp A, S1-S29.
  4. Brixner DI, Watkins JB, Oderda G, Sifford-Wilson SM, Biskupiak JE, Dunn JD, Holtorf AP (). "This drug may work, but is it worth the cost?" can comparative effectiveness research help tame rising health care costs? [Abstract]. J Manag Care Pharm, 5 Supp A, S1-S29.
  5. Albright F, Bollu V, Kuo KL, Raimundo K, Barney R, Stenehjem D, Brixner DI (). IS1: Integrating Data Source To Conduct Comprehensive Oncology Based Outcomes Research. Novartis Pharmaceuticals Corporation [Abstract]. ISPOR 16th Annual International Meeting.
  6. Marcus R, Brixner DI, LaStayo P (). Fat Modulates the Relationship Between Sarcopenia and Physical Function in Non-Obese Older Adults [Abstract]. Current Gerontology and Geriatric Research.
  7. Albright F, Bollu V, Kuo KL, Raimundo K, Barney R, Stenehjem D, Brixner DI (). ISI: Integrating Data Source to Conduct Comprehensive Oncology Based Outcomes Research: Novartis Pharmaceuticals Corporation [Abstract]. ISPOR 16th Annual International Meeting. Baltimore, MD.
  8. Brixner DI, Oderda G (). Application of Economic Evaluation Tools from the United States and Europe Toward Pricing and Reimbursement Strategies in the Asia-Pacific Region [Abstract]. ISPOR 4th Asia-Pacific Conference. Phuket Thailand.
  9. Brixner DI, Oderda G (). Application Towards Integrated Learning of the Medical Pipeline in the PharmD Curriculum [Abstract]. AACP Annual Meeting. Seattle, WA.
  10. Brixner DI, Biskupiak J, Holtorf AP (). Current and Future Use of Health Economic and Outcomes Research Data in Decision Making [Abstract]. European Society of Medical Decision Making Workshop. Tyrol, Austria.
  11. McAdam Marx C, Bouchard J, Aagren M, Nelson R, Brixner D (In Press). Analysis of glycaemic control and weight change in patients initiated with human or analog insulin in an US ambulatory care setting [Abstract]. Diabetes, Obesity and Metabolism, 12(1), 54-64.
  12. Brixner DI, Ye X, Chu Teng-Chiao, Blumentals WA, Hassaniein TI (2009). Meta-analysis estimate of number needed to treat (NNT) to achieve a composite outcome (A1C less than 7 percent, no weight gain and no hypoglycemia) for liraglutide, a human glucagon-like peptide-1 (GLP-1) analog, across six randomized controlled trials [Abstract]. Am J Health-Syst Pharm, 66(Nov).
  13. Brixner DI, Herring R, Gwadry-Sridhar, Femida (). Assessment of Adherence in Hpertension: A Workshop on Issues and Challenges [Abstract]. HTAi 6th Annual Meeting, Singapore.
  14. Brixner DI, McAdam-Marx C, Nelson R, Aagren M, Bouchard J (). Analysis of Glycemic Control and Weight Changes in Patients Treated with Analog Basal Insulin in a Real-World Setting [Abstract]. American Diabetes Association 69th Annual Scientific Meeting. New Orleans, LA.
  15. Fabunmi R, McAdam-Marx C, Ye X, Misurski D, Brixner DI (). Blood Pressure Outcomes After 6 Months of Exenatide Treatment in Patients with Type 2 Diabetes in a Real World Study [Abstract]. American Diabetes Association 69th Annual Scientific Meeting. New Orleans, LA.
  16. McAdam-Marx C, Brixner DI, X Ye, Misurski D, Fabunmi R (). A1C and Weight Outcomes Following 6 Months of Analog Basal Insulin in Insulin Naive Patient with Type 2 Diabetes in an Ambulatory Care Setting [Abstract]. 14th Annual International Meeting International Society of Pharmacoeconomics and Outcomes research (ISPOR). Orlando, FL.
  17. Brixner DI, McAdam-Marx C, X Ye, Misurski D, Wintle M, Fabunmi R (). 18 Month A1C and Weight Outcomes of Exenatide Therapy in Patients with Type 2 Diabetes in a Real-World Study [Abstract]. 14th Annual International Meeting International Society of Pharmacoeconomics and Outcomes Research (ISPOR). Orlando, FL.
  18. McAdam-Marx C, Yu J, Shankar V, Bouchard J, Brixner DI (). Daily Average Consumption of Basil Insulin in Patients with Type 2 Diabetes [Abstract]. 14th Annual International Meeting International Society of Pharmacoeconomics and Outcomes Research ISPOR. Orlando, FL.
  19. Brixner DI, Biskupiak JE, Buysman E, Reynolds M (). PRR-06: Effects on Resource Utilization of Ranolazine in the Treatment of Angina Patients in Managed Care [Abstract]. AMCP 21st Annual Meeting and Showcase. Orlando, FL.
  20. Biskupiak JE, Brixner DI, Hilkert R, Levy DG (). Effectiveness of Amlodipine/Valsartan Single-Pill Combination Therapy in Primary Care [Abstract]. ACCP/ESCP International Congress on Clinical Pharmacy. Orlando, FL.
  21. Brixner DI, Malone D, Waltkins J (). Advancing the Use of Real World Data in Formulary and Reimbursement Decision Making [Abstract]. AMCP 2008 Educational Conference. Kansas City, MO.
  22. Gold DT, Borisov NN, Steinbuch M, Brixner DI (). Improvement in Quality of Life Among Women Treated with Risedronate: Experience From a 2-Year Randomized Controlled Study [Abstract]. ASMBR 30th Annual Meeting. Montreal, Canada.
  23. Brixner DI, Borisov NN, Purple C (). Excess Medical Cost After A Fragility Fracture During 3-Year Follow-up [Abstract]. ASBMR 30th Annual Meeting. Montreal, Canada.
  24. Ghate SR, Doan J, Nelson R, Van Den Bos J, Brixner DI (). Indirect Costs Associated with Patients Treated for Insomnia: An Employer Perspective [Abstract]. 2008 Spring Research and Practice Forum of the American College of Clinical Pharmacy. Phoenix, AZ.
  25. Hassanein TI, Ye X, Blumentals WA, Brixner DI (). Clinical and Persistency Outcomes in Hepatitis C Patients Treated with Peginterferon Alfa-2a or Peginterferon Alfa-2b Plus Ribavirin [Abstract]. Digest Disease Week. San Diego, CA.
  26. Hassanein TI, Ye X, Blumentals WA, Brixner DI (). Clinical and Persistency Outcomes in Hepatitis C Patients Treated with Peginterferon Alfa-2a or Peginterferon Alfa-2b Plus Ribavirin [Abstract]. 2008 Spring Research and Practice Forum of the American College of Clinical Pharmacy. Phoenix, AZ.
  27. Nickman NA, Haak SW, Harald EA, Holtorf AP, Joshi AV, Kim JW, Brixner DI (). Cost Minimization Analysis of Different Growth Hormone Devices Based on Time-And-Motion Simulations [Abstract]. 13th Annual International Meeting International Society of Pharmacoeconomics and Outcomes Research (ISPOR). Toronto, Canada.
  28. LaFleur J, Nelson RE, McAdam-Marx C, Brixner DI, Ward R (). Patent Extension Policies for Pediatric Indications: An Evaluation of the Impact Within One Drug Class in One State Medicaid Program [Abstract]. Academy Health Research Meeting. Washington, DC.
  29. Brixner DI, McAdam-Marx C, Ye XY, Boye FK, Fabunmi R, Schroeder B (). Real World Six Month Outcomes of Patients Initiating Exenatide in a Primary Care Electronic medical Record Database [Abstract]. 13th Annual International Meeting International Society of Pharmacoeconomics and Outcomes Research (ISPOR). Toronto, Canada.
  30. McAdam-Marx C, Brixner DI, Oberg B (). Estimation of Study Population Size for Effectiveness Outcomes at 6 and 12 Months Via Electronic Medical Records [Abstract]. 13th Annual International Meeting International Society of Pharmacoeconomics and Outcomes Research (ISPOR), Toronto, Canada.
  31. McAdam-Marx C, Brixner DI, Ye X, Sung JC, Kahler KH (). Evaluation of Resistant Hypertension in a Usual-Care Setting [Abstract]. 13th Annual International Meeting International Society of Pharmacoeconomics and Outcomes research (ISPOR). Toronto, Canada.
  32. Ghate SR, Said Q, Rosenblatt LC, Kim E, Pikalov A, Brixner DI (). Real World Association Between Antipsychotic treatment and Weight Gain in an Adolescent Population [Abstract]. International Society of Pharmacoeconomics and Outcomes Research 13th Annual International Meeting ISPOR. Toronto, Canada.
  33. Brixner DI (). Applications In Using Large Databases [short course] [Abstract]. 13th Annual International Meeting. Toronto, Canada.
  34. McAdam-Marx C, Brixner DI, Field R, Metraux S (). Type 2 Diabetes in Youth: 2002 and 2006 Prevalence and Obesity in a Primary Care Setting [Abstract]. 13th Annual International Meeting International Society of Pharmacoeconomics and Outcomes Research (ISPOR) Toronto, Canada.
  35. Ghate SR, Said Q, Huse D, Ben-Joseph R, Brixner DI (). Projected Cost of Cardiometabolic Risk Factors in Commercially Insured Normal and Overweight US Primary Care Patients [Abstract]. 13th Annual International Meeting International Society of Pharmacoeconomics and Outcomes Research (ISPOR). Toronto, Canada.
  36. Shafazand S, Yang Y, Mitsi G, Brixner DI (). Heart Failure Quality of Care: Views From a Nationwide Administrative Claims Database [Abstract]. American Heart Association 9th Scientific Quality of Care Cardiovascular Disease and Stroke. Baltimore, MD.
  37. Brixner DI, McAdam-Marx C, Biskupiak J, Lau HJ, Munger M (). Association of Adverse Events of Antihypertensive Therapy by Age in a Physician Practice National EMR Database [Abstract]. American Heart Association Quality of Care Cardiovascular Disease and Stroke. Baltimore, MD.
  38. McAdam-Marx C, Brixner DI, Asche C (). Identifying Potential Adverse Events in an Electronic Medical Record Database [Abstract]. Annual Utah Health Services Research Conference. Salt Lake City, UT.
  39. Brixner DI (). Workshops: Principles of Pharmacoeconomics an Efficacy to Effectiveness [Abstract]. ISPOR 1st International Summer School. Istanbul, Turkey.
  40. Brixner DI (). Utilization of Real World Data in Decision Making [Abstract]. First Annual Turkey ISPOR Chapter Meeting. Antalya, Turkey.
  41. Hassanein TI, Ye X, Blumentals WA, Brixner DI (). Clinical and Persistency Outcomes in Hepatitis C Patients Treated with Peginterferon Alfa-2a or Peginterferon Alfa-2b Plus Ribavirin [Abstract]. 43rd Annual Meeting European Association for the Study of the Liver (EASL). Milan, Italy.
  42. Kane S, Magowan S, Accortt N, Brixner DI (). Predictors of 5-ASA Prescription Persistence During the Chronic Phase in Patients with Ulcerative Colitis [Abstract]. American College of Gastroenterology Annual Scientific Meeting. Philadelphia, PA.
  43. Brixner DI, Neumann PJ, White JT (). Bridging the Gap Between Health Outcomes Research Information and Formulary Decisions: Utilization of the Real World Task Force Report [Abstract]. Academy of Managed Care Pharmacy Educational Conference. Boston, MA.
  44. Brixner DI, Ghate SR, McAdam-Marx C, Maio V (). Analysis of Prescribing Patterns of Antihypertensive Agents (AA) Before and After Publication of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) [Abstract]. International Society of Pharmacoeconomics and Outcomes Research ISPOR 1st Latin America Conference. Cartagena, Columbia.
  45. Nickman N, Haak S, Holtorf AP, Joshi A, Brixner DI (). Time-And-Motion Evaluation of Different Growth Hormones Formulations [Abstract]. International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 10th Annual European Congress. Dublin, Ireland.
  46. Brixner DI, Jackson K, Oberg B, Keskinaslan A, Sheng X (). Factors Influencing Compliance with Combination Antihypertensive Pharmacotherapy in a Large US Database [Abstract]. International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 10th Annual European Congress. Dublin, Ireland.
  47. Oderda G, Brixner DI, Lieberman M (). Comparison of EMR Data to US National Data [Abstract]. International Society of pharmacoeconomics and Outcomes research ISPOR 10th Annual European Congress. Dublin, Ireland.
  48. Muszbek N, Brixner DI, Benedict A, Keskinaslan A, Khan ZM (). The Economic Consequences of Noncompliance in Diabetes and Cardiovascular Disease and Related Conditions: A Review of the Literature [Abstract]. International Society of Pharmacoeconomics and Outcomes Research ISPOR 1st Latin America Conference. Cartagena, Columbia.
  49. Brixner DI, Jackson K, Sheng X, Biskupiak J, Keskinaslan A (). Compliance with Multiple Combination Antihypertensive Pharmacotherapy in a Large US Database [Abstract]. International Society of Pharmacoeconomics and Outcomes Research (ISPOR) European Conference. Dublin, Ireland.
  50. Brixner DI, Horowicz-Mehler N, Stern L, Doyle J, Dolgistr M, Hagan M, PhD (). Contraceptive and Non-Contraceptive Benefits of a Levonorgestrel-Releasing Intrauterine System in a Vertically Integrated HMO [Abstract]. ISPOR 12th Annual International Meeting. Arlington, VA.
  51. Brixner DI, Said Q, Ghate S, McAdam-Marx C (). Correlation of Weight to Cardiometabolic Risk as Identified by ICD-9 Diagnosis Codes and Prescriptions in Primary Care. [Presentation] [Abstract]. ISPOR 12th Annual International Meeting. Arlington, VA.
  52. Brixner DI (). Utilizing Large Databases in Outcomes Research [short course] [Abstract]. ISPOR 12th Annual International Meeting. Arlington, VA.
  53. Brixner DI, Ghate SR, McAdam-Marx C, Maio V (). Analysis of Prescribing Patterns of Antihypertensive Agents(AA) Before and After Publication of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) [Abstract]. 2nd Western Pharmacoenconomics Conference. Salt Lake City, UT.
  54. Brixner DI, Oderda G, Kirkness C, Said Q (). Assessment of Cardiometabolic Risk in an National Primary Care Electronic Medical Database (EMR) [Abstract]. Academy of Managed Care Pharmacy 19th Annual Meeting and Showcase. San Diego, CA.
  55. Jackson KC, Brixner DI, Oderda G, Oberg B, Sheng X, Keskinaslan A (). A Compliance and Persistence of Fixed Dose Versus Free Dose Combination Therapy with Valsartan and HCTZ for Patients with Hypertension [Abstract]. ISPOR 9th Annual European Congress. Copenhagen, Denmark.
  56. McAdam-Marx C, Joish VN, Brixner DI, Hoblyuk R (2006 June). A Comparison of Adherence and Cost of Sulfonylureas in Combination with TZDs or Metaformin. P.2053-PO [Abstract]. ADA 66th Specific Meeting.
  57. Brixner DI, Maio V (). Analysis of Prescribing Patterns of Antihypertensive Agents (AA) Before and After Publication of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) [Abstract]. ISPOR 9th Annual European Congress. Copenhagen, Denmark.
  58. LaFleur J, Asche CV, McAdam-Marx C, Alder S, Sheng X, Brixner DI (). Postmenopausal Osteoporosis Occurrence and Fracture Rates by Age in a Primary-care Setting [Poster] [Abstract]. American Society of Health-System Pharmacists 41st Midyear Clinical Meeting. Anaheim, CA.
  59. Brixner DI, Joish VM, McAdam-Marx C, Arondekar B, Hoblyuk R (2006 April). Evaluation of Persistence and Outcomes in Patients on SU Combination Therapy with TZDs or Metformin. PPRR6 [Abstract]. AMCP 18th Annual Meeting. Seattle, WA.
  60. Brixner, DI (2005, November). Documentation of Pharmacy cost in the preparation of chemotherapy infusions in academic and community-based oncology practices [Abstract]. International Society of Pharmacoeconomics and Outcomes Research (ISPOR) European Conference. Florence, Italy.
  61. Joish VN, Brixner DI, LaFleur J, Kirkness C (2005, October). Pharmacoeconomic analysis of ARB therapy in patients with mild-to-moderate hypertension [Abstract]. Academy of Managed Care Pharmacy 2005 Educational Conference. Nashville, TN.
  62. Biskupiak JE, Brixner DI, Oderda GM, Howard K (). Gastrointestinal Complications of Over-the-Counter Non-Steroidal Anti-Inflammatory Drugs. [Presentation] [Abstract]. ACG 70th Annual Scientific Meeting. Honolulu, HI.
  63. Maio V, Yuen E, Brixner DI, Oderda GM, Asche CV, Smith KD, Morgan S (2005, October). Multi-national assessment of outcomes via retrospective databases, Healthcare Policy Development Issues, Contributed Workshops [Abstract]. International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 8th European Congress. Florence, Italy.
  64. Biskupiak JE, Brixner DI, Oderda GM, Howard K (2005 October). Gastrointestinal Complications of over-the-counter non-steroidal anti-inflammatory drugs [Abstract]. ACG 70th Annual Scientific Meeting.
  65. Brixner DI, Corey-Lisle P, Oberg B, Tuomari V, Biskupiak JE (). Complexity of Depression Treatments: Healthcare Utilization and Costs. [Presentation] [Abstract]. APA Annual Meeting. Toronto, Canada.
  66. Brixner DI (). Electronic Medical Records in Outcomes Research: The New Frontier. [Short Course] [Abstract]. Jefferson Medical College. Philadelphia, PA.
  67. LaFleur J, Thompson CJ, Joish VN, Charland S, Oderda GM, Brixner DI (2005). Adherence and persistence with lipid-lowering pharmacotherapy: Effects of the covariates copay and disease severity on probabilities of being categorized as compliant [Abstract]. Pharmacotherapy Outcomes Research Center; Kos Pharmaceuticals, Inc.
  68. Brixner DI, Borisov NN, Burge RT, Steinbuch M (2005). Cost Analysis of Osteoporosis Treatments: A Managed Care Perspective [Abstract]. European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis. Rome, Italy.
  69. Joish VN, Brady E, Stockdale WA, Dirani R, Brixner DI (2005). Identification and diagnosis of COPD in a primary care setting [Abstract]. International Conference American Thoracic Society.
  70. Said Q, Ho MJ, Beckwith MC, Brixner DI (2005, April 21-25). A Pharmacoeconomic comparison of Oral Fluorquinolones for Complicated Urinary Tract Infections [Abstract]. Academy of Managed Care Educational Conference.
  71. LaFleur J, Thompson C, Ho MJ, Stockdale WA, Charland S, Oderda GM, Brixner DI (2005). Adherence, persistence, and cost of lipid-lowering pharmacotherapy: ER-niacin/statin combination therapy within a single dosage-form versus two separate dosage forms in a managed care population [Abstract].
  72. Brixner DI, Said Q, Newcomer J, Tuomari V, Oderda GM, Stockdale WA, LItalien GJ (2005). Real world usage of weight gain drugs in patients on second-generation anti-psychotics [Abstract]. American Psychiatric Association 158th Annual Meeting.
  73. LaFleur J, Thompson C, Biskupiak J, Stockdale W, Oderda GM, Brixner DI (). Compliance, Adherence and Persistence: A Comparison of Three Metholologies for Evaluating Patient Compliance using Prescription Claims Data [Abstract]. ISPOR 7th Annual European Congress. Hamburg, Germany.
  74. Brixner DI, Tabb K (2004, May). Overview of databases used in managed care research [Abstract]. International Society of Pharmacoeconomics and Outcomes Research.
  75. Brixner DI, Cannon HE, Oderda GM, Stockdale WA, Joish VN, Hanson D (2004). Impact of Varying CoPays on Patient prescribing Behavior in a Managed Care Organization: Focus on Hypertension [Presentation] [Abstract]. Academy of Managed Care 16th Annual Meeting and Showcase. San Francisco, CA.
  76. Brixner DI, Avey SG, Malone D (2003, May). Practical decision analysis for the decision maker. [Presentation] [Abstract]. International Society of Pharmacoeconomics and Outcomes Research Spring Meeting. Arlington, VA.
  77. Oderda LH, Stockdale WA, Oderda GM, Donaldson G, Ashburn M, Brixner DI, Lipman AG (2003, May). Age and gender-stratified differences in quality of life in elderly chronic pain patients [Abstract]. International Society of Pharmacoeconomics and Outcomes Research Spring Meeting.
  78. Brixner DI, Cannon HE, Oderda GM, Biskupiak JE, Stockdale WA, Joish VN, Hanson D (2003, April). Impact of varying copays on patient prescribing behavior in a managed care organization; preliminary results. [Presentation] [Abstract]. Academy of Managed Care Pharmacy 15th Annual Meeting. Minneapolis, MN.
  79. Brixner DI, Tabb K (2003, April). Overview of database used in managed care research. [Presentation] [Abstract]. Academy of Managed Care Pharmacy 15th Annual Meeting. Minneapolis, MN.
  80. Brixner DI, Todd W (2002, April). Compliance and persistency programs as a component of disease management programs in managed care. [Presentation] [Abstract]. Academy of Managed Care Pharmacy 14th Annual Meeting. Salt Lake City, UT.
  81. Brixner DI, Shoheiber O, Polino C, Lin C (1997). Analysis of Compliance across Four Therapeutic Drug Classes in a Pharmacy Claims Database [Abstract]. Academy of Managed Care Pharmacy Annual Meeting.
  82. Brixner DI, Sasane R, Goodwin W (1997). Step Analysis of Patients Initiated on ACEI or CCB Therapy in a Managed Care Setting [Abstract]. Academy of Managed Care Pharmacy Annual Meeting.
  83. Duchane J, Brixner DI, Growboski B, Gunter M (). Identification of Patients with Seizure Disorders in a Managed Care Setting [Abstract]. Association of Pharmacoeconomics and Outcomes Research. Washington, D.C.
  84. Duchane J, Brixner DI, Growboski B, Gunter M (1997). Identification of Patients with Seizure Disorders in a Managed Care Setting [Abstract]. Association of Pharmacoeconomics and Outcomes Research.
  85. Brixner DI, Holtorf AP (1996). Pharmaceutical Manufacture's Role in Disease Management [Presentation] [Abstract]. University of Arizona Conference: Disease Management - Fact or Fantasy, Tucson, AZ.
  86. Brixner DI, Lauper P (1995). Global Pharmacoeconomics: Impact on the US Managed Care Market [Abstract]. Academy of Managed Care Pharmacy 7th Annual Meeting, Tampa, FL.
  87. Brixner DI (1995). Pharmacoeconomics in Formulary Decision Making [Abstract]. International Institute of Research Seminar.
  88. Brixner DI (1995). Monoclonal Antibodies in the Changing Health Care Environment [Abstract]. International Congress of Pharmaceutical Biotechnology.
  89. Brixner DI (1994). Utilization Evaluation of Nabumetone in a Managed Care Setting: A Case Study [Abstract]. Nabumetone Consultant's Update Meeting.
  90. Demarinis RM, Little A, Health Economic Group, Brixner DI (1994). Economic Analysis of Nabumetone, Ibuprofen, and Combination Ibuprofen and Misoprotol in the Treatment of Elderly Patients with Osteoarthritis [Abstract]. Academy of Managed Care Pharmacy 6th Annual Meeting, Chicago, IL.
  91. DeMarinis RM, Little AD, Health Economic Group, Schainbaum S, Brixner DI (1993). Economic Analysis of Paroxetine vs. Imipramine in the Treatment of Depressed Outpatients [Abstract]. California Society of Hospital Pharmacists Annual Meeting, San Francisco, CA.
  92. Riker K, Brixner DI, Priest J, Woodle D, Hammond L, Srinivasan A, Fitzberg AL, Morgan AC Jr (1990). Disulfide Immunoconjugates of 6MP Using the Drug's Intrinsic Thiol [Abstract].
  93. Demarinis RM, Arthur D Little Health Economic Group, Brixner DI (1990). Economic Analysis of Nabumetone, Ibuprofen, and Combination Ibuprofen and Misoprotol in the Treatment of Elderly Patients with Osteoarthritis [Abstract].
  94. Rao TN, Brixner DI, Kasina S, Srinivasan A, Wester DW, Vanderheyden JL, Fritzberg AR (1990). Synthesis and Stability Evaluation of Small Molecule Hydrazones Toward Therapeutic Immunoconjugates [Abstract].
  95. Wester DW, Rao TN, Brixner DI, Srinivasan A, Kasina S, Fitzberg AR (1989). Synthesis and Characterization of the Tc-99 Complex of a Complex of a Bifunctional Ligand Used for Protein Labeling [Abstract].
  96. Brixner DI, Broom AD (1987). N-10-Thymidylyl-8-deazafolate as a Mechanistic Probe of the Thymidylate Synthetase Reaction [Abstract].
  97. Brixner DI, Broom AD (1986). Approaches Toward Pyridine Ring Reduction in the Convergent Syntheses of a Multisubstrate Inhibitor of Thymidylate Synthetase [Abstract].
  98. Kuehl M, Avery T, Brixner DI, Broom AD, Newton PA, Blakley DL (1986). Evaluation of the Non-Hydroxylatable Antifolates 8-Deaza-Methotrexate (8-DMTX) and 8-Deazaaminopterin (8-DAMT) and Comparison with Methotrexate (MTX) and Aminopterin (AMT) [Abstract].
  99. Brixner DI, Bayomi S, Eissa H, Broom AD (1986). Novel Active Site Probe of Thymidylate Synthetase [Abstract].
  100. Brixner DI, Broom AD (1985). Synthesis of N10-Alkyl-Substituted Multisubstrate Inhibitors of Thymidylate Synthetase [Abstract].
  101. Brixner DI, Broom AD (1984). Synthesis of N10-propargyl Derivatives of 8-Deazafolate and 8-Deazaaminopterin [Abstract].
  102. Brixner, DI (). Evaluation of Pharmacy and therapeutic (P & T) Committee Member Knowledge, Attitudes and Ability Regarding the Use of Comparative Effectiveness Research (CER) in Health Care Decision-Making. Journal of Contining Education in the Health Profession [Abstract]. Journal of Continuing Education in the Health Profession.
  103. Schwarzer R, Rochau U, Saverno K, Jahn B, Bornschein B, Lackner M, Sroczynski G, Schall I, Schnell-Inderst P, Flatscher-Thni M, Gothe H, Pugner K, Brixner DI, Siebert U (). Do existing cost-effectiveness thresholds adequately support decision making for PCM? A review of international practice. Oslo, Norway, June 10 -12, 2012 [Abstract]. 14th Biennial European Meeting of the Society for Medical Decision Making (SMDE Europe 2012).
  104. Stanford J, Martin J, Gibson M, Birdsall E, Brixner DI (). Use of Clomiphene Citrate in the University of Utah Community Clinics [Abstract]. The Journal of Reproductive Medicine.
  105. Brixner DI, Bron M, Bellows B, Ye X, Yu J, Raparla S, Oderda G (). Evaluation of Cardiovascular Risk Factors, Events and Costs Accross 4 BMI Categories [Abstract]. Obesity.

Other

  1. Brixner, DI (). Clinical Reflection: Patient Access to Insulin and Noninsulin Diabetes Therapies. (April, 17(3), pp. S13). Supplemental to Journal of Manage Care Pharmacy.
  2. Brixner, DI (). Acknowledgement from Qayyum R, Green L. AHRQ's Comparative Effectiveness Research on Premixed Insulin Analogues for Adults with Type 2 Diabetes: Understanding and Applying the Systematic Review Findings. (17(3), pp. S1-S19). Supplemental to Journal of Managed Care Pharmacy.
  3. Brixner DI (). Future Trends in Using Health Economics and Outcomes Research Data in Formulary Decision Making [Round-Table]. St. Louis, MO: AMCP 2010 Educational Conference.
  4. Hassanein T, Xin Y, Blumentals WA, Prabhakar A, Brixner, DI (). Letter to the Editor: Treatment Rates and Clinical Outcomes in Patients with Hepatitis C: Results from a US-Based Health Plan Analysis.
  5. Brixner DI (). International Health Economics and Outcomes Research Advisory Board Person. Copenhagen, DK.
  6. Brixner DI (). The Use of Real World Data to Assess Compliance and Economics in Hypertension. [Workshop]. Athens, GR: ISPOR 11th Annual European Congress.
  7. Brixner, DI (). The Use of Real World Data to Assess Compliance and Economics in Hypertension [Workshop]. Seoul, South Korea: ISPOR 3rd Asia Pacific Conference.
  8. Brixner, DI (). Comparative Effectiveness: What Are We Comparing? (Presidents Message). ISPOR Connections.
  9. Brixner, DI (). Translational Research and the Value Equation. ISPOR Connections [President's Message].
  10. Brixner, DI (). Reflections on the Quality of the QALY. (December(2007)). ISPOR Connections [President's Message].
  11. Brixner, DI (). Prevalence and Burden of Migraine and the Impact on Managed Care. Currents: Pain Management News and Research. (16(7)). E-Newsletter of the American Academy of Pain Management.
  12. Brixner, DI (). Prescription Drug Spending Around the World: Does Anyone Have it Right? (Oct 2007). ISPOR Connections [President's Message].
  13. Brixner DI, Miller P, Fox J, Calbrese D, Tangalos E, Gruber J, Skinner N (). The Role of Observational Data in Clinical Decision-making for Osteoporosis: Commentaries from Managed Care and Senior Care. [C.E. Program]. (March 2007). Hotwire for Managed Markets.
  14. Brixner DI (1987). Inhibitors of Thymidylate Synthetase: A Mechanistic Probe. Thesis Dissertation.